Daniel Canter¹, Alexander Kutikov¹, Eric M. Horwitz², Richard E. Greenberg¹

Canadian Journal of Urology, Vol.18, No.4, pp. 5844-5848, 2011

Abstract Surgical treatment for men with localized prostate cancer —open, laparoscopic, or robotically-assisted-- remains one of the therapeutic mainstays for this group of patients. Despite the stage migration witnessed in patients with prostate cancer since the introduction of prostate-specific antigen (PSA) screening, detection of extraprostatic disease at the time of surgery and biochemical recurrence following prostatectomy pose signifi cant therapeutic challenges. Radiation therapy (RT) after radical prostatectomy (RP) has been associated with a survival benefi t in both the adjuvant and salvage setting. Nevertheless, optimal targeting of the prostate bed following surgery remains challenging. The Calypso… More >

Franklin E. Kuehhas¹, Ralph Naegele¹, Elisabeth Eckersberger², Markus Margreiter¹, Ralf Herwig¹, Amir Kazzazi², Bob Djavan²

Canadian Journal of Urology, Vol.18, No.4, pp. 5811-5818, 2011

Abstract Introduction: To compare the commonly used 0-1 pad definition of urinary continence for postoperative functional outcome after radical prostatectomy and the correlation with self-reported urinary continence and to determine whether a patient questionnaire can deliver more accurate continence status rates.
Material and methods: We evaluated a cohort of 873 men who underwent radical prostatectomy (RP) at the General Hospital in Vienna between 1998 and 2006. Patients were surveyed with a questionnaire regarding their postoperative outcome and postoperative urinary incontinence. Baseline and pathological factors were examined to determine whether or not they had an impact on the continence status.
… More >

Wally Mahfouz¹, Gilles Karsenty², Jacques Corcos¹

Canadian Journal of Urology, Vol.18, No.4, pp. 5787-5795, 2011

Abstract Introduction: The first application of botulinum toxin type A (BoNT-A) in urology was its injection into the urinary sphincter to treat neurogenic detrusor-sphincter dyssynergia (DSD) in quadriplegic men. Since that first report by Dyskatra et al in 1988, the results of focal BTA injections into the sphincter, the bladder wall and lately into the prostate have raised the interest of the urology community in this promising new therapeutic modality. This is an evidence-based review of the current indications, techniques and outcomes of BTA injections into the urethral sphincter.
Materials and methods: The Medline database was searched for… More >

Benjamin T. Ristau, Jeffrey J. Tomaszewski, Anil V. Parwani, Michael C. Ost

Canadian Journal of Urology, Vol.18, No.5, pp. 5914-5915, 2011

Abstract We present the case of a 69-year-old male with incidentally discovered capillary hemangiomas at radical prostatectomy. Hemangiomas of genitourinary origin are extremely rare, typically benign vascular tumors. This finding represents the first reported hemangioma within a radical prostatectomy specimen. More >

Jonathan N. Warner¹, Rafael N. Nunez¹, Chinedu O. Mmeje¹, Thomas V. Colby², Robert G. Ferrigni¹, Mitchell R. Humphreys¹, Paul E. Andrews¹, Erik P. Castle¹

Canadian Journal of Urology, Vol.18, No.6, pp. 6043-6049, 2011

Abstract Introduction: We evaluate the impact of margin length, location, and pathologic stage on biochemical recurrence (BCR) after robot assisted radical prostatectomy (RARP) at 37 months of follow up.
Materials and methods: A total of 1420 patients underwent a robot assisted radical prostatectomy between March 2004 and May 2010. Patients who received adjuvant therapy, those who never achieved an undetectable prostate-specific antigen (PSA), and those who had less than 18 months of follow up were excluded. Patients were then divided and evaluated based on margin status.
Results: In total, 419 patients were included in the analysis. Eighty-three had a… More >

Dean S. Elterman^1,2, Jack Barkin^1,3, Sidney B. Radomski¹, Neil E. Fleshner¹, Brian Liu¹, Kira Bensimon¹, Samantha Arora¹, Michael Robinette¹, Antonio Finelli¹

Canadian Journal of Urology, Vol.18, No.6, pp. 6037-6042, 2011

Abstract Introduction: High-intensity focused ultrasound (HIFU) is a non-invasive technique that uses focused ultrasound waves to ablate tissue. This retrospective study evaluates the early HIFU experience at a single Canadian center.
Materials and methods: Ninety-five patients were treated between March 2006 and December 2007 using the Sonablate 500 device (Focus Surgery, Indianapolis, IN, USA). Follow-up was conducted at 3-month intervals and included serial prostate-specific antigen (PSA) measurements, assessment of erectile function using the International Index of Erectile Function (IIEF), and evaluation of continence rates using the Expanded Prostate Cancer Index Composite (EPIC) questionnaire. Early and late complications were… More >

Gina M. Badalato¹, Matthew S. Wosnitzer¹, Matthew D. Truesdale¹, Marco Sandri², Woo Jin Ko¹, Jaime Landman¹, Ketan K. Badani¹

Canadian Journal of Urology, Vol.18, No.6, pp. 6031-6036, 2011

Abstract Introduction: Bioimpedance spectroscopy (BIS) is a novel, precise quantification of body composition (BC) using low electrical currents through tissue. Accurate BC quantification may better predict postoperative outcomes. We compared BIS-BC and body mass index (BMI) for correlation with post-surgical outcomes in robotic assisted radical prostatectomy (RARP) patients.
Materials and methods: Preoperative BIS-BC and BMI analyses were conducted on men with biopsy-proven prostate cancer undergoing RARP. Height, weight, percentage and fat mass (PFM, FM), percentage and fat-free mass (PFFM, FFM), percentage and total body water (PTBW, TBW), and percentage and intracellular/extracellular water (PICW, PECW, ICW, ECW) were obtained… More >

Pim J. van Leeuwen, Roderick C. N. van den Bergh, Tineke Wolters, Xiaoye Zhu, Meelan Bul, Fritz H. Schröder, Chris H. Bangma, Monique J. Roobol

Canadian Journal of Urology, Vol.18, No.6, pp. 6018-6024, 2011

Abstract Introduction: The value of characteristics assessed prior to diagnosis in predicting aggressive prostate cancer, metastases, and mortality in men participating in a screening study were identified.
Materials and methods: This study included 19,950 men aged 55 to 74 years at first screening in the European Randomized Study of Screening for Prostate Cancer. Factors such as age, Charlson comorbidity index, family history of prostate cancer, vasectomy status, International Prostate Symptom Score (IPSS), digital rectal examination (DRE) status, transrectal ultrasound (TRUS) findings, prostate volume, and prostate-specific antigen (PSA) level were evaluated. Participants were followed for a median of 11.1… More >

Jack M. Zuckerman, Britton Tisdale, Kurt McCammon

Canadian Journal of Urology, Vol.18, No.6, pp. 6013-6017, 2011

Abstract Introduction: This study aims to evaluate the complication rate and efficacy of the AdVance sling (American Medical Systems, Minnetonka, MN, USA) in patients with stress urinary incontinence (SUI) and a history of pelvic radiation.
Materials and methods: A retrospective chart review was conducted of all men at our institution with a history of prostate cancer and subsequent radiation therapy who were treated with an AdVance sling for SUI.
Results: Between 2007 and 2009, the AdVance sling procedure was performed in 27 patients with prior pelvic radiation therapy. The mean patient age was 73.2 years. At an average follow-up… More >

VIJAY L. KUMAR^* AND BISWA M. PADHY

BIOCELL, Vol.35, No.3, pp. 63-70, 2011, DOI:10.32604/biocell.2011.35.063

Abstract Calotropis species have been used in the traditional medicinal system for the treatment of diseases of the liver and abdomen. In view of the antioxidant and anti-hyperglycemic properties of an aqueous suspension obtained from the dried latex of Calotropis procera, the present study was carried out to evaluate its efficacy in affording protection against alloxan induced changes in rat kidney. A single intraperitoneal injection of alloxan (150 mg/kg) in rats produced hyperglycemia within 3 days and altered kidney functions over a period of 90 days. Daily oral administration of the aqueous suspension (100 and 400 mg/kg) in… More >